New York, Jan 14, 2026, 11:12 EST — Regular session
- Kenvue shares gained roughly 0.4% in mid-morning trading amid investor attention on its upcoming sale to Kimberly-Clark.
- Kimberly-Clark submitted new deal-related documents to U.S. regulators, which included screenshots from a joint transaction website.
- KVUE is currently priced about 5% below the implied value of the agreed cash-and-stock deal.
Kenvue Inc shares ticked up roughly 0.4% to $17.08 on Wednesday, continuing a stretch of modest fluctuations as the stock moves mainly on deal speculation. The gain followed Kimberly-Clark’s submission of extra documents to the U.S. Securities and Exchange Commission related to its intended purchase of the consumer health firm.
Timing is key. Kenvue shareholders will vote on the deal on Jan. 29 at 9:00 a.m. ET, with most ballots expected by the night before, per the deal site. leadinghealthandwellness.com
Under the deal, Kenvue shareholders will get $3.50 in cash plus 0.14625 Kimberly-Clark shares for each Kenvue share they own. With Kimberly-Clark’s stock at $98.87, that works out to roughly $17.96 per Kenvue share—about 88 cents shy of the headline figure, marking a discount near 5%. “We are excited to bring together two iconic companies,” Kimberly-Clark CEO Mike Hsu stated at the announcement. Kenvue CEO Kirk Perry added it “unites two highly complementary portfolios.” investors.kenvue.com
The deal spread reflects the difference between Kenvue’s current trading price and the payout investors expect if the takeover wraps up as scheduled. This gap can fluctuate as traders reevaluate the chances of closing and the duration their capital will remain locked in.
The latest SEC filing was brief but highlights that the campaign is nearing its final phase. Kimberly-Clark reported submitting screenshots of a transaction website related to the deal.
Since Kimberly-Clark stock is part of the deal, the implied buyout price shifts alongside it. When announced, the companies set total consideration at $21.01 per Kenvue share, tied to Kimberly-Clark’s closing price on Oct. 31, 2025—but the numbers have changed since then.
The companies anticipate the deal will close in the second half of 2026, pending shareholder and regulatory approvals along with standard conditions. Kimberly-Clark has secured financing from JPMorgan and intends to cover the cash portion with a mix of cash on hand, new debt, and proceeds from the earlier announced sale of a majority stake in its international tissue and professional business.
Still, there’s room for things to go off track. A cash-and-stock deal can unravel fast if the stock tanks, regulators drag their feet, or shareholders reject the terms — and Kenvue’s discount signals the market is factoring in those risks.
Traders are zeroed in on the vote mechanics and clues from major shareholders as the meeting looms. The next key date is Jan. 29, when Kenvue shareholders will vote on whether to merge with Kimberly-Clark or remain independent.
